[2/11/2021, Nantong] Ractigen Therapeutics, a leading company in the saRNA drug space, announced that it has closed a 17$ million USD (￥110 million) Series A financing round led by Hillhouse Venture Capital with participation from CCB Healthcare Growth Fund, Boyi Capital, and Longman Capital to support advancement of its lead ph

[May 19^th, 2020] Today, CB Insights China published, for the first time, a top list of RNA biotech companies in China and Ractigen Therapeutics, as the only company developing RNAa therapeutics, is listed as top 3.

[July 11, 2018] Today, a 5-member delegation, led by the dean Professor Fei Sun, from Nantong University Medical School paid a visit to Ractigen and Rudong Life and Health Industry Park.

[Feb.

The 6th RNAi China conference was held on October 10th and 11th at Kunshan as expected. A host of leading experts in the fields of oligonucleotide research and drug development from both academia and industry including Ractigen Therapeutics’s CEO Dr.

[Rudong, China] The grand opening ceremony of Ractigen Therapeutics took place on the morning of June 18th, 2017 in front of Ractigen’s building in the Life-Health Industrial Park, Rudong, Jiangsu.

Springer•Nature published a book edited by Ractigen’s founder, Dr. Long-Cheng LI and entitled “RNA Activation”. This is the first published book on RNAa and was contributed by over 40 worldwide experts working on RNAa. 

Henry Stewart Talks which publishes animated audio visual presentations by world leading experts published a lecture by Dr. Long-Cheng Li.

On September 2, 2016, Ractigen Therapeutics was officially incorporated and registered with the Industry and Commerce Bureau of Nantong, Jiangsu Province.